If you have any doubts, you can contact us anytime
The "right model" is access with guardrails, qualified clinicians, licensed pharmacies, validated quality testing and "meaningful" patient follow-up, according to the expert
Semaglutide 2.4mg (GLP-1 Agonist): Proven GLP-1 effects (appetite suppression, gastric emptying) Already FDA-approved as Wegovy Established safety profile Cagrilintide 2.4mg (Amylin Analog): Mimics amylin, a hormone co-secreted with insulin Slows gastric emptying through different pathway than GLP-1 Reduces appetite through hindbrain (not hypothalamus) Improves postprandial glucose The Advantage: Leverages proven semaglutide efficacy and safety, adds complementary amylin effects
This initial dosage, while not effective for glycemic control, is crucial for treatment initiation
In people without ADHD a meta-analysis of 48 placebo-controlled trials found only small effects on inhibitory control and memory, and its authors noted that much of what healthy users feel may be improved energy and motivation rather than faster thinking